- High grade ovarian cancer, including high grade serous; clear cell; endometrioid, grade 3; and others (adenocarcinoma, NOS; mixed epithelial carcinoma; undifferentiated carcinoma).
- Recurrent, platinum resistant ovarian cancer (defined as progression within < 6 months from completion of platinum based therapy.
- 1-2 prior regimens (including primary therapy). Hormonal therapies (e.g., tamoxifen, aromatase inhibitors) will not count toward the prior regimen limit.
- Performance Status 0, 1 or 2
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.